Eli Lilly’s retatrutide notched a late-stage milestone for next-generation weight-loss therapy in TRIUMPH-2, with the company reporting dose-dependent weight loss of up to 22%+ in people with obesity and type 2 diabetes, alongside broad cardiometabolic improvements. Lilly said about six in 10 participants on the highest dose moved to BMI levels no longer meeting obesity criteria after 80 weeks. The results add pressure to the competitive obesity pipeline as “GLP-3” candidates move toward regulatory review, particularly because TRIUMPH-2 also included changes in blood sugar, cholesterol and blood pressure—risk factors tied to cardiovascular outcomes. The dataset positions retatrutide as a potential step-change versus earlier GLP-1 and dual-agonist benchmarks. At the same conference cycle, analysts and clinicians also continued to pressure-test other multi-agonist approaches. Separate Phase 2 updates discussed at the EASD meeting suggested dosing details could swing perceived efficacy, keeping attention on how these programs translate into clinically meaningful endpoints. Taken together, the retatrutide readout underscores that efficacy breadth—weight plus metabolic and cardiovascular risk markers—has become central for late-stage obesity differentiation.